Aboriginal & Torres Strait Islander Care: Improving Breast Cancer Outcomes

How can breast cancer surgery achieve the best cancer outcomes while also considering the appearance and shape of the breast? In this episode, we sit down with Professor Elisabeth Elder to explore oncoplastic breast surgery and some of the important questions that remain unanswered. Professor Elder discusses how oncoplastic techniques are used, the role of shared decision-making, where gaps in the evidence still exist, and how research and clinical trials could help shape the future of breast cancer surgery. (2:29) Where are the biggest gaps that remain in this field? (6:34) What kinds of research are currently underway, and how can it help to answer some of the questions being highlighted within your presentation on oncoplastic breast surgery? (8:38) Where do you see the next 5-10 years in this area of research? (9:19) What would be your key message to clinicians about this area of research? Tune in for a deep dive into this important research. Like this episode? ⁠⁠ Follow Breast Cancer Trials on Social Media: Instagram:⁠ ⁠⁠@breastcancertrials⁠⁠ Facebook:⁠ ⁠⁠⁠Breast Cancer Trials⁠⁠ LinkedIn: ⁠⁠Breast Cancer Trials⁠⁠ X: ⁠⁠⁠⁠@BCTrialsANZ⁠⁠ Guest: Breast Surgeon, Professor Elisabeth Elder. Thank you for listening! If you found this episode valuable, please share it with your loved ones and help spread awareness about the importance of clinical trials research.

Breast cancer treatment can bring on menopause suddenly or make existing symptoms more severe, significantly affecting a woman's quality of life. In this episode, we sit down with Dr Christina Jang to explore the challenges of managing menopause during and after breast cancer treatment. Dr Jang discusses common symptoms, the treatment and management options available, the importance of balancing symptom relief with cancer care, and why a holistic approach to menopause can make a valuable difference to women's wellbeing. (1:24) What are the most common symptoms of menopause that you see in patients, and how do these impact quality of life? (2:22) How has our understanding of the safe and effective management of menopause evolved over recent years? (3:29) What are some of the current treatment approaches available, and how do clinicians work with patients to determine the best treatment plan? (4:35) How important is a holistic approach to care, and who else should be involved in a patient's treatment? Tune in for a deep dive into this important research. Like this episode? ⁠⁠ Follow Breast Cancer Trials on Social Media: Instagram:⁠ ⁠@breastcancertrials⁠ Facebook:⁠ ⁠⁠Breast Cancer Trials⁠ LinkedIn: ⁠Breast Cancer Trials⁠ X: ⁠⁠⁠@BCTrialsANZ⁠ Guest: Endocrinologist, Dr Christina Jang. Thank you for listening! If you found this episode valuable, please share it with your loved ones and help spread awareness about the importance of clinical trials research.

Treatment for triple-negative breast cancer has advanced significantly, but challenges remain when, in some cases, the disease returns after treatment. In this episode, we sit down with Dr Belinda Yeo to explore treatment options for triple-negative breast cancer patientswhose cancer has that has relapsed. Dr Yeo discusses the challenges clinicians face when deciding what treatment to offer next, emerging therapies showingpromise, and the critical role that clinical trials continue to play in improving outcomes for people with triple-negative breast cancer. (3:03) If a patient's cancer does return after these therapies, what are clinicians' biggest challenges in determining what treatment to offer next? (04:21) As a clinician, what treatment approaches or emerging therapies for triple-negative breast cancer are giving you the most optimism? (06:05) How important is participation in clinical trials? (07:21) What is one key message that you'd like patients navigating triple-negative breast cancer to take away from this episode? Tune in for a deep dive into this important research. Like this episode? ⁠⁠ Follow Breast Cancer Trials on Social Media: Instagram:⁠ @breastcancertrials Facebook:⁠ ⁠Breast Cancer Trials LinkedIn: Breast Cancer Trials X: ⁠⁠@BCTrialsANZ Guest: Medical Oncologist, Dr Belinda Yeo. Thank you for listening! If you found this episode valuable, please share it with your loved ones and help spread awareness about the importance of clinical trials research.

Invasive lobular carcinoma is the second most common type of breast cancer, yet there is still much to learn about what makes this disease biologically distinct. In this episode, we sit down with Associate Professor Amy McCart Reed to explore the molecular underpinnings of invasive lobular carcinoma. Associate Professor McCart Reed discusses what researchers are learning about the biology of invasive lobular carcinoma, recent discoveries shaping our understanding of the disease, and how this research could ultimately lead to more personalised treatments and better outcomes for people living with a lobular diagnosis. (2:01) What have been some of the biggest discoveries in recent years that are changing the way researchers think about this subtype of breast cancer? (02:57) Are we aiming to move more towards personalised treatment for breast cancer? (03:27) What research still needs to happen in this space? (05:17) What is the key message that you'd like researchers and clinicians to take away from this episode? Tune in for a deep dive into this important research. Donate to support live-saving research. Like this episode? ⁠⁠ Follow Breast Cancer Trials on Social Media: Instagram:⁠ ⁠@breastcancertrials Facebook:⁠ ⁠Breast Cancer Trials LinkedIn: ⁠⁠Breast Cancer Trials X: ⁠⁠@BCTrialsANZ Guest: Molecular Biologist, Associate Professor Amy McCart Reed. Thank you for listening! If you found this episode valuable, please share it with your loved ones and help spread awareness about the importance of clinical trials research.

Could Patients with Breast Cancer Safely Skip Radiation & the Potential Side Effects? Inside the ROSALIE Clinical Trial Could skipping radiation after breast-conserving surgery be safe for some patients? The ROSALIE trial is exploring this possibility. In this episode, we sit down with Professor Boon Chua, Radiation Oncologist and Professor of Medicine at the University of New South Wales, who leads the Breast Cancer Trials ROSALIE clinical trial. Professor Chua discusses how the study aims to de-escalate treatment for women with early-stage breast cancer who achieve a complete response to chemotherapy, potentially reducing side effects without compromising outcomes. (2:06) What is the ROSALIE clinical trial hoping to find out? (2:51) How could this research change the way we treat breast cancer in the future, especially for patients with early-stage disease? (3:30) What would you like patients and the public to understand about the importance of participating in trials like this? Tune in for a deep dive into this important research. ⁠⁠⁠⁠Donate to Support Life-Saving Research⁠⁠⁠⁠ Like this episode? ⁠⁠⁠⁠Find more Breast Cancer Trials Podcast Episodes here⁠⁠⁠⁠ Follow Breast Cancer Trials on Social Media: Instagram:⁠ ⁠⁠⁠@breastcancertrials⁠⁠⁠⁠ Facebook:⁠ ⁠⁠⁠Breast Cancer Trials⁠⁠⁠⁠ LinkedIn: ⁠⁠⁠⁠Breast Cancer Trials⁠⁠⁠⁠ X: ⁠⁠⁠⁠@BCTrialsANZ⁠⁠⁠⁠ Guest: Medical Oncologist, Dr Boon Chua. Thank you for listening! If you found this episode valuable, please share it with your loved ones and help spread awareness about the importance of clinical trials research.